Trial Profile
A Safety and Efficacy Study of Autologous Chimeric Antigen Receptor Engineered T Cells Redirected to EGFRvIII in Patients With Recurrent Glioblastoma Multiforme
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Jul 2019
Price :
$35
*
At a glance
- Drugs Anti-EGFRvIII CAR T cells (Primary) ; Cyclophosphamide; Fludarabine
- Indications Glioblastoma
- Focus Adverse reactions
- 01 Aug 2016 New trial record